Adamis Pharmaceuticals Corporation

0.7160-0.0216-2.93%Vol 2.37M1Y Perf 101.77%
Apr 16th, 2021 11:20 DELAYED
BID0.7128 ASK0.7160
Open0.7500 Previous Close0.7376
Pre-Market0.75 After-Market-
 0.01 1.68%  - -
Target Price
1.25 
Analyst Rating
Moderate Buy 2.33
Potential %
74.51 
Finscreener Ranking
+ —    -
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
     41.37
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★+     42.73
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap96.09M 
Earnings Rating
Neutral
Price Range Ratio 52W %
19.75 
Earnings Date
17th May 2021

Today's Price Range

0.69010.7582

52W Range

0.31632.34

5 Year PE Ratio Range

-2.90-3.30

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-16.71%
1 Month
-29.75%
3 Months
-5.44%
6 Months
-20.16%
1 Year
101.77%
3 Years
-79.79%
5 Years
-90.93%
10 Years
-77.75%

TickerPriceChg.Chg.%
ADMP0.7160-0.0216-2.93
AAPL133.95-0.5500-0.41
GOOG2 295.03-1.6300-0.07
MSFT259.510.01000.00
XOM56.96-0.0200-0.04
WFC43.130.89002.11
JNJ161.330.94000.59
FB306.16-1.6600-0.54
GE13.46-0.0900-0.66
JPM153.191.02000.67
Financial StrengthValueIndustryS&P 500US Markets
1.00
1.30
0.09
0.25
-201.20
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
12.00
-187.30
-169.00
-219.00
-
RevenueValueIndustryS&P 500US Markets
8.23M
0.06
-4.35
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020--0.16-
Q03 2020-0.04-0.10-150.00
Q02 2020-0.07-0.13-85.71
Q01 2020-0.05-0.10-100.00
Q04 2019--0.08-
Q03 2019-0.06-0.11-83.33
Q02 2019-0.12-0.16-33.33
Q01 2019-0.15-0.19-26.67
Earnings Per EndEstimateRevision %Trend
12/2020 FY-0.375.13Positive
3/2021 QR-0.05-66.67Negative
6/2021 QR-0.05-25.00Negative
12/2021 FY-0.19-26.67Negative
Next Report Date17th May 2021
Estimated EPS Next Report-0.05
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume2.37M
Shares Outstanding134.20M
Trades Count3.34K
Dollar Volume8.62M
Avg. Volume17.29M
Avg. Weekly Volume3.64M
Avg. Monthly Volume2.80M
Avg. Quarterly Volume18.21M

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) stock closed at 0.7376 per share at the end of the most recent trading day (a -7.02% change compared to the prior day closing price) with a volume of 4.19M shares and market capitalization of 96.09M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 171 people. Adamis Pharmaceuticals Corporation CEO is Dennis J. Carlo.

The one-year performance of Adamis Pharmaceuticals Corporation stock is 101.77%, while year-to-date (YTD) performance is 52.05%. ADMP stock has a five-year performance of -90.93%. Its 52-week range is between 0.3163 and 2.34, which gives ADMP stock a 52-week price range ratio of 19.75%

Adamis Pharmaceuticals Corporation currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 4.86, a price-to-sale (PS) ratio of 14.47, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -68.89%, a ROC of -87.87% and a ROE of -98.11%. The company’s profit margin is -%, its EBITDA margin is -169.00%, and its revenue ttm is $8.23 Million , which makes it $0.06 revenue per share.

Of the last four earnings reports from Adamis Pharmaceuticals Corporation, there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Adamis Pharmaceuticals Corporation’s next earnings report date is 17th May 2021.

The consensus rating of Wall Street analysts for Adamis Pharmaceuticals Corporation is Moderate Buy (2.33), with a target price of $1.25, which is +74.51% compared to the current price. The earnings rating for Adamis Pharmaceuticals Corporation stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adamis Pharmaceuticals Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adamis Pharmaceuticals Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 23.79, ATR14 : 0.13, CCI20 : -193.28, Chaikin Money Flow : -0.25, MACD : -0.11, Money Flow Index : 30.43, ROC : -17.49, RSI : 36.99, STOCH (14,3) : 2.63, STOCH RSI : 0.29, UO : 41.23, Williams %R : -97.37), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adamis Pharmaceuticals Corporation in the last 12-months were: David J. Marguglio (Option Excercise at a value of $0), David J. Marguglio (Sold 116 498 shares of value $73 423 ), Dennis J. Carlo (Option Excercise at a value of $0), Dennis J. Carlo (Sold 31 507 shares of value $19 436 ), Karen K. Daniels (Sold 15 668 shares of value $9 675 ), Robert O. Hopkins (Option Excercise at a value of $0), Robert O. Hopkins (Sold 76 179 shares of value $43 260 ), Ronald B. Moss (Option Excercise at a value of $0), Ronald B. Moss (Sold 25 017 shares of value $15 445 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
2 (66.67 %)
3 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.33
Moderate Buy
2.33
Hold
3.00

Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company. It is focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy, and opioid overdose. Its SYMJEPI (epinephrine) Injection products are used in the emergency treatment of acute allergic reactions, including anaphylaxis.

CEO: Dennis J. Carlo

Telephone: +1 858 997-2400

Address: 11682 El Camino Real, San Diego 92130, CA, US

Number of employees: 171

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

67%33%

Bearish Bullish

59%41%

Bearish Bullish

57%43%

News

Stocktwits